CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zhejiang Jolly Pharmaceutical Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zhejiang Jolly Pharmaceutical Co Ltd
Zhiyuan Road, Wukang Town, Deqing County
Phone: +86 5728281383p:+86 5728281383 HUZHOU, ZHJ  313200  China Ticker: 300181300181
Business Summary
Zhejiang Jolly Pharmaceutical Co Ltd is a China-based company primarily engaged in the research and development, production, and sales of pharmaceuticals. The Company’s main products include the Wuling series (Wuling Capsule, Lingze Tablet, Linglianhua Particle), the Bailing series (Bailing Tablet and Bailing Capsule), traditional Chinese medicine decoction pieces and traditional Chinese medicine formula granules, calcium polycarbophil Tablets and others. The Wuling Capsule is mainly used in departments such as psychiatry, neurology, traditional Chinese medicine, otolaryngology, dermatology, gastroenterology, cardiology, oncology, and endocrinology. The Lingze Tablet is mainly used in departments such as urology, traditional Chinese medicine andrology, and andrology. The Company mainly conducts its business in the domestic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
5122 Drugs, drug proprietaries, and druggists' sundries
5047 Medical, dental, and hospital equipment and supplies

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board YouqiangYu 63 8/27/2003 8/27/2003
Chief Financial Officer, Deputy General Manager LiYe 49 4/18/2022 4/18/2022
General Manager, Director TaoWang 57 5/10/2024 1/16/2018
11 additional Officers and Directors records available in full report.

Business Names
Business Name
300181
Baicao Traditional Chinese Medicine

General Information
Number of Employees: 2,861 (As of 12/31/2024)
Outstanding Shares: 701,387,335 (As of 6/30/2025)
Shareholders: 33,820
Stock Exchange: SHE
Fax Number: +86 5728281246


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, October 23, 2025